Journal
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
Volume 19, Issue 6, Pages 764-769Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/cbr.2004.19.764
Keywords
cancer; immunotherapy; cytokines; vaccine adjuvants; microspheres; controlled-release
Categories
Funding
- NCI NIH HHS [CA085097] Funding Source: Medline
Ask authors/readers for more resources
Controlled-release, injectable polymer microspheres provide a clinically feasible alternative to gene-modification for the local, sustained delivery of cytokines to tumors for cancer immunotherapy. Long-term release kinetics, bioactivity profiles, and stability of interleukin-2 (IL-2), interleukin-12 (IL-12), and granulocyte-macrophage colony-stimulating factor (GM-CSF)-encapsulated microspheres prepared by phase inversion nanoencapsulation (PIN) were evaluated. While all formulations released physiologically relevant quantities of cytokine for up to 30 days, the individual release kinetics were different. Recovery of specific activity after encapsulation was 40%, 60%, and 90% - that of pre-encapsulation levels for IL-2, GM-CSF and IL-12, respectively. Upon storage, the IL-12 microspheres rapidly lost activity, whereas IL-2 and GM-CSF microspheres remained stable for at least 9 weeks. These studies demonstrate that bio-chemical properties of microsphere formulations vary depending on the cytokine, and rigorous characterization of formulations is a prerequisite to in vivo testing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available